Looking at the filing content, I need to check for substantive disclosure content beyond boilerplate. The filing contains the cover page, forward-looking statements section, and a risk summary section. The risk summary bullets contain substantive disclosure about the company's financial condition (going concern doubt, no revenue from product sales, loan agreement restrictions, etc.). This is more than 150 words of substantive content, so I proceed. The cover page shows: Trading Symbol "CALC" on "The Nasdaq Capital Market" - so NASDAQ:CALC. The filing is a 10-Q for the quarterly period ended September 30, 2026, filed November 10, 2026. Shares outstanding as of November 5, 2026: 6,895,149. Key substantive disclosures: going concern doubt, no product revenue, need for additional capital, loan agreement restrictions, clinical-stage company.

CalciMedica, Inc. (NASDAQ:CALC) filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 10, 2026, disclosing going concern doubt and continued net losses as a clinical-stage biopharmaceutical company.

Key Highlights

  • Going concern doubt disclosed: The filing states that the company's "need for additional capital raises substantial doubt about our ability to continue as a going concern."
  • No product revenue: According to the filing, CalciMedica "has never generated any revenue from product sales and may never be profitable."
  • Shares outstanding: As of November 5, 2026, the company reported 6,895,149 shares of common stock outstanding.
  • Loan agreement restrictions: The filing discloses that "the terms of the Loan Agreement place restrictions on our operating and financial flexibility."
  • Clinical-stage status: The company described itself as "a clinical-stage biopharmaceutical company with a limited operating history" and a "history of net losses."
  • Additional funding required: The filing states the company "will need to obtain substantial additional funding to complete the development and any commercialization of our product candidates."

CalciMedica Flags Capital Needs and Going Concern Risk in September 2026 Quarter Filing

CalciMedica, Inc., listed on the Nasdaq Capital Market under the symbol CALC, submitted its quarterly report for the period ended September 30, 2026. The filing identifies the company as a clinical-stage biopharmaceutical company headquartered at 505 Coast Boulevard South, Suite 300-9, La Jolla, CA 92037. The company reported 6,895,149 shares of common stock outstanding as of November 5, 2026, and is classified as a non-accelerated filer and smaller reporting company.

Among the most significant disclosures in the filing is the company's statement that its need for additional capital "raises substantial doubt about our ability to continue as a going concern." The filing states that if the company is "unable to raise this capital when needed, on acceptable terms, or at all," it "may be forced to delay, reduce or eliminate the development of our product candidates or other operations." The filing further notes that the company has never generated revenue from product sales. The company's lead product candidate referenced in the filing is Auxora, described in connection with its CRAC channel inhibition science, which the filing describes as "based on novel technologies that are unproven."

The filing also highlights that the existing Loan Agreement places restrictions on operating and financial flexibility, and that raising additional capital through equity or debt could cause dilution to stockholders or further restrict operations. Forward-looking statements in the filing regarding cash runway, clinical trial timing, and regulatory approvals are described by the company as subject to known and unknown risks and uncertainties, and the company notes it is "under no duty to update or revise any of the forward-looking statements" except as required by law.

What Was Disclosed

CalciMedica filed its Form 10-Q for the quarter ended September 30, 2026, disclosing going concern doubt, no product revenue history, 6,895,149 shares outstanding as of November 5, 2026, and ongoing capital needs to fund development of its product candidates including Auxora.